Cite this: HMG-CoA Reductase Inhibitors in Kidney Transplant Recipients Receiving Tacrolimus: Statins not Associated with Improved Patient or Graft Survival - Medscape - Apr 01, 2010. Abstract and ...

HMG-CoA reductase inhibitors, commonly referred to as statins, are the cornerstone of pharmacologic reduction of elevated low-density lipoprotein cholesterol. LDL-C is the main contributor to ...

HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma J I Cohen 1 British Journal of Cancer volume 92 , pages 1593–1598 ( 2005 ) Cite this article ...

A literature search was completed using MEDLINE (1966 February 7, 2004) and EMBASE (1980 December 2003) using the following search terms: C-reactive protein, statin or HMG-CoA reductase inhibitors ...

When compared with patients taking bile acid-binding resins, patients taking HMG-CoA reductase inhibitors were 28% less likely to be diagnosed with any cancers. With the exception of lymphoma, use of ...

The HMG CoA reductase inhibitor simvastatin was a generous gift from MRL (Merck & Co., Inc., Rahway, NJ). Six- to eight-week-old male Sprague-Dawley rats (200 g initial weight) were given standard ...

Some statins work best in the evening, while others work just as well in the morning. The best time to take statins depends ...

HMG-CoA reductase inhibitors (statins) have recently become a target of investigation for expanding the armamentarium of agents that reduce morbidity and mortality in influenza.

Statins, or HMG-CoA reductase inhibitors, are considered a standard therapy for many types of dyslipidemia and are generally “administered in the evening because cholesterol biosynthesis peaks ...

Genetic inhibition of HMG-CoA reductase, a state that mimics long-term statin use, was associated with greater risk for developing cataract compared with individuals without genetic inhibition ...

Statins (HMG-CoA reductase inhibitors) have been used for the treatment of hypercholesterolemia and coronary artery disease for more than a decade. Their efficacy and safety have been well documented ...

Conclusions: HMG CoA reductase inhibitors are associated with a 51% reduction in the risk of colorectal cancer, and the protective effect is specific to this class of lipid-lowering agents. The ...